Dyne Therapeutics
- Market cap
- 2.98B
- P/E (TTM)i
- -4.90
- P/Bi
- 4.25
- EPSi
- -3.47
- Div yieldi
- 0.00%
- 52W posi
- 17%
Anonymous reader poll. Unscientific, not investment advice.
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
- Founded
- 2017
- CEO
- Mr. John G. Cox
- Employees
- 258
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- dyne-tx.com
Company profile
- Exchange
- US
- Symbol
- DYN
- Market-cap rank
- #2540
- Listing date
- 2020-09-17
- Market cap
- 2.98B
- Float cap
- 2.97B
- Shares out
- 186.75M
- Float shares
- 186.24M
Sectors & themes
Quote time 2026-10-08 06:20:44 · For reference only, not investment advice and not tailored to your situation.